Gilead Sciences closed Thursday at $170.68, up 9.4% on the week, after a third-quarter earnings beat prompted one of the most unified rounds of analyst target upgrades the stock has seen in recent memory. The catalyst was Wednesday's Q3 print. Gilead raised full-year revenue guidance to $30.0 to $30.4 billion, driven by continued strength in its HIV franchise. Biktarvy and Descovy…
GILD short interest jumps 20% in one week to 1.77% of free float, now at 22.0M shares as of October 14. Cost to borrow eases to 0.55%, with over 1.2B shares available to lend.
Key data as of 4 Nov 2026
GILD short interest jumps 20% in one week to 1.77% of free float, now at 22.0M shares as of October 14. Cost to borrow eases to 0.55%, with over 1.2B shares available to lend.
3 Short Interest updates in 30 days
GILD cost to borrow jumps to 0.7%, up 103% in one week, as short covering accelerates.
Gilead Sciences closed Thursday at $170.68, up 9.4% on the week, after a third-quarter earnings beat prompted one of the most unified rounds of analyst target upgrades the stock has seen in recent memory. The catalyst…
Short sellers are fleeing GILD. The options market is leaning bullish. The two signals are pointing the same way. Short interest fell 20.3% in a single day on September 24. It now stands at just 1.47% of free float —…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for GILD — free to start on ORTEX.
Sign up for free →Open GILD on ORTEX